HCV-related liver transplantation and post-transplant survival rates in Europe have improved rapidly

April 13, 2018, European Association for the Study of the Liver

HCV-related liver transplantation rates in Europe have declined dramatically since the availability of direct-acting antiviral (DAA) drugs and survival rates after transplantation have reached an all-time high. A study presented today at The International Liver Congress 2018 in Paris, France, has found that the percentage of liver transplants performed as a result of hepatitis C virus (HCV) infection has more than halved since the availability of DAA drugs, and that post-transplant survival rates among those with HCV infection are now similar to those reported in patients with hepatitis B virus (HBV) infection.

"Direct-acting antiviral drugs have revolutionized the treatment of HCV-infected individuals—even those with advanced liver disease," explained Dr. Giovanni Perricone from the ASST Great Metropolitan Hospital Niguarda in Milan, Italy, who presented the study findings today. "Unlike the older HCV treatment regimens involving ribavirin and pegylated interferon, these newer agents are highly effective and well tolerated across genotypes, and we have shown previously that the remarkable clinical improvements that can be achieved using these agents can lead to the delisting of some individuals waiting for liver transplantation."

In the latest research conducted by Dr. Perricone and colleagues, data from the European Liver Transplant Registry from between January 2007 and June 2017 were reviewed, involving a total of 36,382 adults who underwent liver transplantation as a result of HCV, HBV, or non-alcoholic steatohepatitis (NASH). To assess the impact of DAAs on liver transplantation rates, data were analyzed in separate treatment eras: the interferon (IFN) era from 2007 to 2010, the protease inhibitor (PI) era from 2011 to 2013, and the second-generation DAA era from 2014 to June 2017.

The percentage of conducted as a result of HCV decreased from 22.8% during the IFN era to 10.6% during the DAA era. In contrast, the percentage of transplants conducted as a result of NASH increased from 1.1% to 6.2%. Within the DAA era, the percentage of liver transplants due to HCV decreased from 21.1% during the first half of 2014 to 10.6% during the first half of 2017.

According to Dr. Perricone, the decreased requirement for liver transplantation during the DAA era was more pronounced in patients with HCV related to decompensated (-68.8%) than in those with HCV-related hepatocellular carcinoma (-34.0%). The 3-year survival of liver recipients with HCV infection has also improved from 65.1% in the IFN era to 76.9% in the DAA era—a survival rate that is now comparable to that of patients with HBV infection (78.0%) (p=0.38).

"Our study provides clear evidence that DAAs are changing the epidemiology of , at least in countries like Italy where the prevalence of HCV infection is high," said Dr. Perricone. "We anticipate that rates of HCV-related transplantation will continue to decline as more patients gain access to these highly effective treatments."

"For the first time in many years, we have also seen improved survival in transplant recipients with HCV infection, and this can be attributed directly to the availability of DAA drugs."

"These are very important data that emphasize the effectiveness of DAA therapies against HCV," said Prof. Markus Cornberg from the Hannover Medical School, Germany, and EASL Governing Board Member. "These data are important, especially as a recent Cochrane report has concluded that there is not sufficient evidence to understand how sustained virological response affects long-term clinical outcomes."

Explore further: Alcoholic liver disease replaces hepatitis C infection as the leading cause of liver transplantation

Related Stories

Alcoholic liver disease replaces hepatitis C infection as the leading cause of liver transplantation

April 11, 2018
Two independent studies have today reported that alcoholic liver disease has now replaced hepatitis C virus (HCV) infection as the leading cause of liver transplantation in the USA in patients without HCC. Non-alcoholic steatohepatitis ...

Antiviral drug prevents recurrence of hepatitis C in liver transplant patients

January 10, 2017
Patients with hepatitis C virus infection who received an antiviral drug around the time they underwent liver transplantation saw a high rate of sustained virologic response, according to a Northwestern Medicine phase II ...

Treatment of HCV allows for sustained removal from the liver transplant waiting list

April 21, 2017
A new European study presented today demonstrated that patients with chronic Hepatitis C virus (HCV) and severe liver damage, taken off the liver transplant list as a result of successful direct-acting antiviral (DAA) therapy, ...

Use of direct-antiviral agents helps overcome hepatitis C recurrence in liver transplant patients

April 25, 2015
New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation ...

20-year survival expected for 4 out of 5 children who receive liver transplants

April 14, 2016
A new study presented today shows that 20-year survival after childhood liver transplantation can be expected for almost 80% of patients. The study, presented at The International Liver CongressTM 2016 in Barcelona, Spain, ...

New data reveals positive outcomes for hepatitis C transplant patients

April 11, 2014
New research announced at the International Liver Congress 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).

Recommended for you

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.